Eyesense

EyeSense is developing a continuous blood glucose monitoring system (CGM), FiberSense, with the aim of improving the standard of care for diabetics. The Company’s system utilizes innovative technologies that differentiate it from other CGM devices, particularly by improving measurement accuracy, increasing usage time prior to replacement and reducing cost.

CEO

Dr Achim Mülle
Sub segment
Medical Device
Location
Grossostheim, Germany

Related companies

Rosetta Capital
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.